INFLUENZA virus vaccines have always been prepared from virus grown in embryonated eggs and traditionally consisted of inactivated whole virus. Some degree of purification of the virus from egg contaminants was accomplished by use ofthe Sharples international centrifuge. The end-product vaccine still contained a considerable amount of egg protein and the vaccines frequently produced local and febrile reactions. An important advance came with use of the zonal centrifuge to further purify the vaccine virus in a density gradient (Reimer et al., 1967) . Another * Taken from an article originally published in the Journal of Infectious Diseases (1972) 125, 656. Requests for reprints: Frederick L. Ruben, Department of Medicine, Montefiore Hospital, 3459 Fifth Avenue, Pittsburgh, Pa. 15213. advance came when the influenza virion was disrupted by treatment with ether. Vaccines prepared in this manner contained the envelope proteins (haemagglutinin and neuraminidase) of the -virion separated from the nucleoproteins. Febrile responses were diminished and the antigenicity of the virus retained (Davenport et al., 1964) .
Recently a new method for disrupting the influenza virion was reported by Neurath et al. (1970 . A dispersant tri-(n-butyl) phosphate, or TNBP, was used to release the envelope proteins of the virus. Egg constituents were removed from the viral components by column separation. Some potential advantages of the method over disruption of the virus with ether are: that the TNBP-treated virus vaccine was less pyrogenic when given to rabbits, the virus was disrupted at very low v/v TNBP concentrations, and TNBP is non-volatile and, hence, safer for mass production techniques.
In clinical trials with TNBP-produced subunit vaccine, we have compared the local and systemic reactions and the immunologic response with other prototype influenza vaccines. With the new vaccine, high doses beyond those well-tolerated with conventional preparations also have been investigated.
Materials and methods

Vaccines
Subunit tri-(n-butyl) phosphate vaccines were prepared by Wyeth Laboratories from egg grown A2/Aichi/2/68 and B/Mass/3/66 influenza viruses. (Sever, 1962) . Heterologous haemagglutinins were obtained from the National Center for Disease Control, Atlanta, Georgia.
Neutralization tests
Sera were heat-inactivated at 56°C for 30 min, and then serially diluted in monkey kidney maintenance media at pH 7-6. An equal volume, 0 4 ml containing 100 TCID50/0O1 ml of tissue culture adapted A./Aichi/2/68 or B/Mass/3/66 virus was added and the mixture allowed to sit at room temperature for 1 hr, then 0-2 ml of the mixture at each serum dilution was added to each of three tubes of monkey kidney cells in tissue culture. The cultures were incubated on a roller drum at 34°C for 3 days. At this time the replication of influenza virus was determined by the haemadsorption test with 0-5%o guinea-pig erythrocytes.
Nasal washing specimens were lyophylized to dryness, reconstituted with 3 0 ml saline, and tested for the presence of haemoglobin by Hematest (Ames Laboratories). All positive specimens were discarded. Aliquots of haemoglobin negative specimens were heat inactivated as above and handled exactly as serum for neutralization testing except that 10 TCID50/01 ml was used as the virus inoculum and tubes were tested for haemadsorption after 4 days. A positive nasal washing neutralization test was defined as a four-fold rise in titre if there was a prevaccine titre, or any rise in titre if the prevaccine specimen at 1: 2 dilution was negative. All paired nasal washings were run simultaneously.
Complement fixation tests
Paired serum specimens were tested using standard micro-titre complement fixation procedures (Sever, 1962) with overnight fixation at 4°C and two full units of complement. A commercial soluble (S) antigen of Influenza A and B was used.
Results
Safety of the TNBP vaccine
Two hundred and two sera representing sixty-seven volunteers were tested for abnormalities by the SMA 12/60 automated test. None of the sera tested showed abnormalities either prior to receiving the vaccine, or at 48 hr and 10 days after vaccination.
Vaccines given at conventional dosage Figure 1 shows the effect of route of administration on the production of local and systemic sidereactions from the different influenza virus vaccines.
The three vaccines given s.c., Sharples, zonal and TNBP subunit, all caused maximal pain responses of an intensity over 2. The vaccines given i.m., the subunit ether and subunit TNBP, had lower maximal pain responses. Erythema and induration at the local site which averaged 4-5 cm in diameter with vaccines given s.c., was hardly measurable in the i.m. vaccinated groups. Upper normal limits for fever were established in controls as 99-40F. Fever was minimal in all groups, both for the number of subjects who had fever and for the height of the temperature rise. vaccinated persons tested. Only one of nine nasal wash specimens tested for neutralizing antibody showed a rise in titre, and this went from less than 2 to a titre of 4. IgA was present in all of the specimens studied at a concentration of 3-6-5 mg/100 ml for the final reconstituted specimen.
Vaccines given at increasing dosage Figure 4 shows the relative freedom from sidereactions with increasing doses of subunit vaccine given i.m. A small dose, 40 Figure 5 shows the magnitude of the increment in HI antibody expressed as geometric average fold rises. All were nearly comparable except for the highest dosage. At 6400 CCA units of A2 (with 4800 CCA units of B) a striking increase in antibody occurred relative to the other dosages which was statistically significant (P= <0-05). Neutralizing antibody titres are not illustrated, but in the highest dose vaccine group they were similarly increased. None of the doses of Influenza B evoked an antibody response in all of the recipients; seroconversion occurred in only thirty-seven of forty-five persons given doses from 300 to 4800 CCA units. Seven of nine responded to 30 CCA units intradermally. Higher dose elicited a greater increment in the magnitude of the antibody response, but the dose effect was significant (P= <0-05) only at the highest dosage.
Sera from 10 days postvaccination are compared with the final specimens in showing the marked increment in titre of antibody achieved following a dose of 6400 CCA units. A similar but less striking effect is seen with Influenza B vaccine at a dose of 4800. Another feature of the curves is that with doses up to 1600 CCA units of A2, the maximum antibody response was not attained until 3-4 weeks after vaccination (the final sera), whereas larger doses of vaccine produced a peak titre earlier with an appreciable decrease after 3-4 weeks.
In Table 2 are the results of tests for HI antibody against heterologous strains of influenza virus. Sera from vaccinees receiving the standard dose, 400 CCA units of A2 and 300 CCA units of B subunit vaccine were compared with sera from vaccinees receiving the highest dosage, which was sixteen times greater. Testing was done with haemagglutinins from three characteristic isolates of A2 from earlier periods, two strains of A1, the human prototype A (PR 8), and A (Swine); also, two earlier strains of Influenza B were used. The paired sera used in these tests had shown rises to both A2/Aichi and B/Mass, the vaccine (Neurath et al., 1970 ) was compared with other available vaccines. Also of interest was the new opportunity afforded by the acceptability of the subunit vaccine to explore the response over a broad range of doses up to sixteen times the standard recommended dose.
For Influenza A2 in the standard dose of 400 CCA units, the subunit vaccine had no apparent advantage over whole virus preparations with regard to the number of people in whom an antibody response was elicited. In the case of Influenza B using 300 CCA units, the subunit preparation was advantageous, but more extensive studies are necessary to make such a conclusion final. Although the magnitude of the rise following i.m. administration of standard dose TNBP subunit A2 vaccine was greater than those following other vaccines, the result could be from differences in the average pre-vaccine antibody titre.
The influence of route administration, and particularly of the i.m. route, on acceptability of influenza vaccines has not received great attention in the literature. Route has been shown to influence antibody responses, particularly with low dosages (Tauraso et al., 1969) . The subunit TNBP vaccine, when given intradermally or subcutaneously, caused reactions comparable with those produced by the Sharples and zonal vaccines. These were typical reactions of delayed hypersensitivity indicating prior sensitization of the recipients to influenza virus antigens or else local cellular recruitment with the liberation of vasoactive substances at the site of antigen injection. Studies to be reported elsewhere suggest the former and also suggest that an increase in the number of specifically sensitized lymphocytes occurred in the blood after vaccination. When the route was switched to i.m., virtually no reactions were noted with the subunit TNBP vaccine, even including the highest CCA unit dosages given. This reduction in local reactions suggests that the vaccine may have disseminated rapidly from the site of injection, which could result in diminished antigenicity. No data are available to know whether there was a decreased stimulus to sensitization of T-lymphocytes, but there was no decrease in antibody response following the i.m. injection of a standard dose of subunit vaccine. In fact, the geometric mean response of antibody titre to the same dose of TNBP subunit Influenza A2 vaccine was better by the i.m. than the s.c. route; the average titre rises were 25-513 against 36-247 respectively. For Influenza B also, a higher mean peak titre was reached after i.m. than s.c. vaccine (1500 against 1180), but the initial mean titre of the group also was higher (200 against 89); therefore, no difference can be assumed.
The observation that i.m. injection of subunit vaccine eliminated the local painful reactions and did not decrease the antibody response, permitted investigation of the response to increasing dosages of vaccine. Mostow et al. (1969) , in one study, compared high (3000 CCA units) dosages of zonal centrifuged vaccines given subcutaneously. They found a two-to three-fold greater incidence of adverse reactions and a ten-fold increase in antibody titres following the higher dose. Phillips et al. (1970) studied zonal centrifuged vaccines in a dose range of 200-800 CCA units and reported local reactions in 19°/ of the volunteers receiving vaccine subcutaneously. They also showed geometric mean titres which increased with the increments in dosage. Mostow et al. (1970) there was no clinical illness in any of the volunteers during the study, we assume that the anti-(S) rises were vaccine-induced, and that the vaccine contains some viral nucleoprotein. The rises confirm the observation of Lief, Henle & Schrack (1960) that inactivated vaccines can induce such rises. In another report, data were published which showed that the standard doses of TNBP subunit vaccine, and all of the other preparations, were effective in stimulating rises in anti-neuraminidase antibody. The magnitude of the response in general paralleled that of the HI antibody . The failure of the TNBP vaccine in standard dosage to induce neutralizing activity in the nasal washings was disappointing. Previous observations using standard vaccine have given varied results (Phillips et al., 1970; Mostow et al., 1970; Fulk et al., 1969) . Intranasal administration of inactivated vaccine can sometimes elicit nasal antibody, but the production of local immunity of the respiratory tract is one of the potential advantages of live virus vaccines under development.
The serum response to TNBP subunit vaccine was rapid, especially when large CCA unit doses were given. These must be assumed to be secondary or booster responses considering that most subjects had pre-existing antibody. The few persons who had no detectable antibody against the vaccine strain, however, also showed prompt seroconversion after subunit vaccine.
It is hoped that the large doses of vaccine which produced many fold increases in the titre of antibodies might also result in a persistent protective level. Data (Fazekas, 1969) . Such responses in humans following zonal centrifuged vaccines are reported in the study of Mostow et al. (1970) . In our study, heterologous antibody responses to previously encountered Influenza A and interrelated B strains were demonstrated following subunit TNBP vaccine. Among strains of Influenza A, heterologous antibodies were produced when a large dose of vaccine was given and were not induced by the standard dose of 400 CCA units. It seems unlikely that small increments in CCA unitage of Influenza A vaccine will be useful for heterologous antibody induction. On the other hand, standard doses of 300 CCA units of Influenza B vaccine readily produced inhibitory antibody against the heterologous strains isolated in earlier periods. These and other biologic differences between Influenza A and B viruses make it prudent to consider the vaccine requirements for each independently as new vaccines are formulated with the possibility of broad variations in the range of dosage. If production of antibody against related heterologous strains is a goal, a reasonable formula, according to our data, might be 300 CCA units of Influenza B with 6400 CCA units of A.
The ability to give relatively large doses of subunit vaccine without producing undesirable side-reactions also permits re-inquiry about the theoretical advantages of a polyvalent vaccine. If adequate doses of antigens from past strains of Influenza A can be included without compromising the effective, protective dose of antigens from recent strains, the likelihood of prophylaxis against more of the natural recombinants of influenza viruses seems probable. A new subunit vaccine appears at least to offer the possibility for such a study. 
